t-butyl 5-(2-ethoxycarbonyl-E-ethenyl)-2-thiophenecarboxylate | 149325-06-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: t-butyl 5-(2-ethoxycarbonyl-E-ethenyl)-2-thiophenecarboxylate
• 英文别名: tert-butyl 5-[(E)-3-ethoxy-3-oxoprop-1-enyl]thiophene-2-carboxylate
• CAS: 149325-06-4
• 化学式: C₁₄H₁₈O₄S
• 分子量: 282.361
• InChiKey: ZIYSKINEEBXXGR-VQHVLOKHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  80.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  t-butyl 5-(2-ethoxycarbonyl-E-ethenyl)-2-thiophenecarboxylate 在 palladium on activated charcoal 氢气 作用下， 以 乙醇 为溶剂， 生成 tert-butyl 5-(2-ethoxycarbonylethyl)thiophene-2-carboxylate
  参考文献：
  名称：

  具有有效抗肿瘤活性的新型6-5稠合环杂环抗叶酸药物：2,4-二氨基-6,7-二氢-5H-环戊[d]嘧啶抗叶酸药物的桥修饰和杂环苯甲酰基等价物。

  摘要：

  结构强大的二氢叶酸还原酶（DHFR）活性和肿瘤细胞生长抑制剂N- [4- [3-（2,4-diamino-6,7-dihydro-5H-cyclopenta [d] pyrimidin-5-] （1）导致了新的基于环戊达[d]嘧啶的抗叶酸的合成，包括具有低烷基取代的亚丙基桥键（2a，b）和等位修饰桥键的化合物（亚乙基氧； 2c；亚乙基氨基2d； 2d，2e，f）的N-甲基和N-乙基衍生物以及其中1的苯环已被杂环等排物取代的化合物（吲哚，2g；二氢吲哚，2h；噻吩， 2i）。这些新的类似物作为DHFR和细胞生长抑制剂非常有效，在暴露于72小时的药物后，它们比甲氨蝶呤（MTX）和10-乙基-10-去氮杂蝶呤（10-EDAM）更有效地抑制肿瘤细胞的生长（对P388 MTX敏感和对MTX耐药，结肠26和KB） 。其中2a（1的10-甲基衍生物）和2i最有效，其效力比10-EDAM高2至3倍。药物暴

  DOI：

  10.1248/cpb.43.829
• 作为产物：
  描述：

  1,3-二甲基-2-(2-噻吩)咪唑烷 在 正丁基锂 、 四甲基乙二胺 、 sodium hydride 、 碘甲烷 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 39.0h， 生成 t-butyl 5-(2-ethoxycarbonyl-E-ethenyl)-2-thiophenecarboxylate
  参考文献：
  名称：

  αvβ3 Antagonists Based on a Central Thiophene Scaffold

  摘要：

  A series of novel, highly potent alpha (v)beta (3) antagonists based on a thiophene scaffold and containing an acylguanidine as an Arg-mimetic is described. A number of structural features, such as cyclic versus open guanidine and a variety of lipophilic side chains, carbamates, sulfonamides and beta -amino acids were explored with respect to inhibition of alpha (v)beta (3) mediated cell adhesion and selectivity versus alpha (IIb)beta (3) binding. In addition, compound 19 was found to be active in the TPTX model of osteoporosis. (C) 2001 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(01)00357-2

文献信息

• Novel 6-5 Fused Ring Heterocycle Antifolates with Potent Antitumor Activity: Bridge Modifications and Heterocyclic Benzoyl Isosters of 2,4-Diamino-6,7-dihydro-5H-cyclopenta(d)pyrimidine Antifolate.
  作者：Yoshihiko KOTAKE、Tatsuo OKAUCHI、Atsumi IIJIMA、Kentaro YOSHIMATSU、Hiroaki NOMURA

  DOI：10.1248/cpb.43.829

  日期：——

  tumor cell growth, N-[4-[3-(2,4-diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidin-5- yl)propyl]benzoyl]-L-glutamic acid (1), have led to the synthesis of new cyclopenta[d]pyrimidine-based antifolates, including those with low alkyl substituted trimethylene bridges (2a, b) and isosterically modified bridges (ethyleneoxa, 2c; ethyleneamino, 2d; the N-methyl- and N-ethyl derivatives of 2d, 2e, f) and those

  结构强大的二氢叶酸还原酶（DHFR）活性和肿瘤细胞生长抑制剂N- [4- [3-（2,4-diamino-6,7-dihydro-5H-cyclopenta [d] pyrimidin-5-] （1）导致了新的基于环戊达[d]嘧啶的抗叶酸的合成，包括具有低烷基取代的亚丙基桥键（2a，b）和等位修饰桥键的化合物（亚乙基氧； 2c；亚乙基氨基2d； 2d，2e，f）的N-甲基和N-乙基衍生物以及其中1的苯环已被杂环等排物取代的化合物（吲哚，2g；二氢吲哚，2h；噻吩， 2i）。这些新的类似物作为DHFR和细胞生长抑制剂非常有效，在暴露于72小时的药物后，它们比甲氨蝶呤（MTX）和10-乙基-10-去氮杂蝶呤（10-EDAM）更有效地抑制肿瘤细胞的生长（对P388 MTX敏感和对MTX耐药，结肠26和KB） 。其中2a（1的10-甲基衍生物）和2i最有效，其效力比10-EDAM高2至3倍。药物暴
• Condensed pyrimidine derivative
  申请人：Eisai Co., Ltd.

  公开号：US05554615A1

  公开（公告）日：1996-09-10

  A novel pyrimidine derivative having an excellent antitumor activity, which is represented by the following general formula (I) or a pharmacologically acceptable salt thereof: ##STR1## wherein R.sup.1 represents a hydroxyl or amino group; R.sup.2 represents a phenylene, pyridinediyl, thiendiyl, furandiyl or thiazoldiyl group, --CO.sub.2 R.sup.5 and --CO.sub.2 R.sup.6 may be the same or different from each other and each represents a carboxyl group or a carboxylic acid ester, the part ##STR2## A represents an oxygen atom, a group represented by the formula: ##STR3## (wherein R.sup.3 and R.sup.4 may be the same or different from each other and each represents a hydrogen or halogen atom or a hydrocarbon group which may be substituted, or alternatively R.sup.3 and R.sup.4 may be united to form an alkylidene group which may be substituted) or a group represented by the formula: ##STR4## (wherein R.sup.70 represents a hydrogen atom or a hydrocarbon group), and n is an integer of 1 to 3, provided that the compound in which R.sup.1 represents oxygen, and hydrogen is attached to nitrogen at 3-position is included in the above shown definition, a process for preparation the same, and an antitumor drug containing the same.

  一种具有优异抗肿瘤活性的新型嘧啶衍生物，其由以下一般式（I）或其药理学上可接受的盐所代表：##STR1## 其中R.sup.1代表一个羟基或氨基团；R.sup.2代表苯基、吡啶基、噻吩基、呋喃基或噻唑基团，--CO.sub.2R.sup.5和--CO.sub.2R.sup.6可以相同也可以不同，每个代表一个羧基或羧酸酯，部分##STR2## A代表氧原子，一个由式表示的基团：##STR3## （其中R.sup.3和R.sup.4可以相同也可以不同，每个代表氢或卤素原子或一个可被取代的碳氢基团，或者R.sup.3和R.sup.4可以结合形成一个可被取代的烷基亚甲基）或一个由式表示的基团：##STR4## （其中R.sup.70代表氢原子或一个碳氢基团），n是1到3的整数，前提是在上述定义中包括R.sup.1代表氧，氢附着在3-位置的氮化合物，一种制备该化合物的方法，以及含有该化合物的抗肿瘤药物。
• Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists
  申请人：Aventis Pharma Deutschland GmbH and Genentech, Inc.

  公开号：US20030153557A1

  公开（公告）日：2003-08-14

  The present invention relates to thienyl substituted acylguanidine derivatives, such as compounds of formula (I) in which R 1 , R 2 , R 4 , R 6 , A, B and D have the meanings indicated in the claims, their physiologically tolerable salts and their prodrugs. The compounds of the present invention are valuable pharmaceutical active compounds. They are vitronectin receptor antagonists and inhibitors of bone resorption by osteoclasts. They are suitable, for example, for the therapy and prophylaxis of diseases which are caused at least partially by an undesired extent of bone resorption, for example of osteoporosis. The invention furthermore relates to processes for the preparation of thienyl substituted acylguanidines, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及噻吩取代的酰基胍衍生物，例如公式(I)中R1、R2、R4、R6、A、B和D所示含义的化合物，它们的生理耐受性盐和前药。本发明的化合物是有价值的药物活性化合物。它们是玻璃蛋白受体拮抗剂和破骨细胞骨吸收抑制剂。例如，它们适用于治疗和预防由于骨吸收不良造成的至少部分疾病，例如骨质疏松症。此外，本发明还涉及制备噻吩取代的酰基胍衍生物的方法，它们的使用，特别是作为药物中的活性成分，并包括它们的制剂。
• Condensed pyrimidine derivatives antitumor agents
  申请人：Eisai Co., Ltd.

  公开号：EP0530579A1

  公开（公告）日：1993-03-10

  A novel pyrimidine derivative having an excellent antitumor activity, which is represented by the following general formula (I) or a pharmacologically acceptable salt thereof:    wherein R¹ represents a hydroxyl or amino group; R² represents a phenylene, pyridinediyl, thiendiyl, furandiyl or thiazoldiyl group, -CO₂R⁵ and -CO₂R⁶ may be the same or different from each other and each represents a carboxyl group or a carboxylic acid ester, the part 〉X-Y-Z- represents 〉N-CH₂-CH₂-, 〉N-CH=CH- or 〉CH-CH₂-CH₂-, A represents an oxygen atom, a group represented by the formula: (wherein R³ and R⁴ may be the same or different from each other and each represents a hydrogen or halogen atom or a hydrocarbon group which may be substituted, or alternatively R³ and R⁴ may be united to form an alkylidene group which may be substituted) or a group represented by the formula: (wherein R⁷⁰ represents a hydrogen atom or a hydrocarbon group), and n is an integer of 1 to 3, provided that the compound in which R¹ represents oxygen, and hydrogen is attached to nitrogen at 3-position is included in the above shown definition, a process for preparation the same, and an antitumor drug containing the same.

  一种具有优异抗肿瘤活性的新型嘧啶衍生物，由以下通式（I）或其药理上可接受的盐表示： 其中 R¹ 代表羟基或氨基；R²代表苯基、吡啶二基、噻吩二基、呋喃二基或噻唑二基，-CO₂R⁵和-CO₂R⁶可以相同或不同，且各自代表羧基或羧酸酯、X-Y-Z-代表〉N-CH₂-CH₂-、〉N-CH=CH-或〉CH-CH₂-CH₂-，A代表氧原子、由式： (其中 R³ 和 R⁴ 可以相同或不同，各自代表氢原子、卤素原子或可被取代的烃基，或者 R³ 和 R⁴ 可以结合形成可被取代的亚烷基）或由式表示的基团： (其中，R⁷⁰ 代表氢原子或烃基，且 n 为 1 至 3 的整数）的化合物、其制备方法以及含有该化合物的抗肿瘤药物均包括在上述定义中。
• THIENYL SUBSTITUTED ACYLGUANIDINES AS INHIBITORS OF BONE RESORPTION AND VITRONECTIN RECEPTOR ANTAGONISTS
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1086098A1

  公开（公告）日：2001-03-28